These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 14553933)
1. The effects of Escherichia coli capsule, O-antigen, host neutrophils, and complement in a rat model of Gram-negative pneumonia. Russo TA; Davidson BA; Carlino-MacDonald UB; Helinski JD; Priore RL; Knight PR FEMS Microbiol Lett; 2003 Sep; 226(2):355-61. PubMed ID: 14553933 [TBL] [Abstract][Full Text] [Related]
2. Capsule and O-antigen from an extraintestinal isolate of Escherichia coli modulate cytokine levels in rat macrophages in vitro and in a rat model of pneumonia. Russo TA; Davidson BA; Beanan JM; Olson R; Holm BA; Notter RH; Knight PR Exp Lung Res; 2007 Sep; 33(7):337-56. PubMed ID: 17849261 [TBL] [Abstract][Full Text] [Related]
3. Capsular polysaccharide and O-specific antigen divergently modulate pulmonary neutrophil influx in an Escherichia coli model of gram-negative pneumonitis in rats. Russo TA; Davidson BA; Priore RL; Carlino UB; Helinski JD; Knight PR Infect Immun; 2000 May; 68(5):2854-62. PubMed ID: 10768982 [TBL] [Abstract][Full Text] [Related]
4. Human neutrophil chemotaxis is modulated by capsule and O antigen from an extraintestinal pathogenic Escherichia coli strain. Russo TA; Davidson BA; Topolnycky DM; Olson R; Morrill SA; Knight PR; Murphy PM Infect Immun; 2003 Nov; 71(11):6435-45. PubMed ID: 14573665 [TBL] [Abstract][Full Text] [Related]
5. Loss of the O4 antigen moiety from the lipopolysaccharide of an extraintestinal isolate of Escherichia coli has only minor effects on serum sensitivity and virulence in vivo. Russo TA; Sharma G; Brown CR; Campagnari AA Infect Immun; 1995 Apr; 63(4):1263-9. PubMed ID: 7890383 [TBL] [Abstract][Full Text] [Related]
6. The O4 specific antigen moiety of lipopolysaccharide but not the K54 group 2 capsule is important for urovirulence of an extraintestinal isolate of Escherichia coli. Russo T; Brown JJ; Jodush ST; Johnson JR Infect Immun; 1996 Jun; 64(6):2343-8. PubMed ID: 8675348 [TBL] [Abstract][Full Text] [Related]
7. Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine. Russo TA; Beanan JM; Olson R; MacDonald U; Cope JJ Vaccine; 2009 Jan; 27(3):388-95. PubMed ID: 19014988 [TBL] [Abstract][Full Text] [Related]
8. E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia model. Russo TA; Davidson BA; Genagon SA; Warholic NM; Macdonald U; Pawlicki PD; Beanan JM; Olson R; Holm BA; Knight PR Am J Physiol Lung Cell Mol Physiol; 2005 Aug; 289(2):L207-16. PubMed ID: 15805136 [TBL] [Abstract][Full Text] [Related]
9. Escherichia coli O-antigen capsule (group 4) is essential for serum resistance. Biran D; Rosenshine I; Ron EZ Res Microbiol; 2020 Mar; 171(2):99-101. PubMed ID: 31982499 [TBL] [Abstract][Full Text] [Related]
10. Roles of interleukin-6 in activation of STAT proteins and recruitment of neutrophils during Escherichia coli pneumonia. Jones MR; Quinton LJ; Simms BT; Lupa MM; Kogan MS; Mizgerd JP J Infect Dis; 2006 Feb; 193(3):360-9. PubMed ID: 16388483 [TBL] [Abstract][Full Text] [Related]
11. CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Wang Q; Teder P; Judd NP; Noble PW; Doerschuk CM Am J Pathol; 2002 Dec; 161(6):2219-28. PubMed ID: 12466136 [TBL] [Abstract][Full Text] [Related]
12. Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats. Karzai W; Cui X; Mehlhorn B; Straube E; Hartung T; Gerstenberger E; Banks SM; Natanson C; Reinhart K; Eichacker PQ Anesthesiology; 2003 Jul; 99(1):81-9. PubMed ID: 12826846 [TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence. Phillips-Houlbracq M; Ricard JD; Foucrier A; Yoder-Himes D; Gaudry S; Bex J; Messika J; Margetis D; Chatel J; Dobrindt U; Denamur E; Roux D Int J Med Microbiol; 2018 Mar; 308(2):290-296. PubMed ID: 29325882 [TBL] [Abstract][Full Text] [Related]
15. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. Horwitz MA; Silverstein SC J Clin Invest; 1980 Jan; 65(1):82-94. PubMed ID: 6985617 [TBL] [Abstract][Full Text] [Related]
16. Capsules of Escherichia coli, expression and biological significance. Jann K; Jann B Can J Microbiol; 1992 Jul; 38(7):705-10. PubMed ID: 1393836 [TBL] [Abstract][Full Text] [Related]
17. The presence of K54 capsular polysaccharide increases the pathogenicity of Escherichia coli in vivo. Russo TA; Liang Y; Cross AS J Infect Dis; 1994 Jan; 169(1):112-8. PubMed ID: 8277173 [TBL] [Abstract][Full Text] [Related]
18. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Russo TA; Beanan JM; Olson R; Genagon SA; MacDonald U; Cope JJ; Davidson BA; Johnston B; Johnson JR Vaccine; 2007 May; 25(19):3859-70. PubMed ID: 17306426 [TBL] [Abstract][Full Text] [Related]